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ABSTRACT
2
Wilson's disease (WD) is a treatable inborn error of metabolism inherited in an autosomal 
recessive fashion (world-wide incidence 1:200,000). WD is a type of copper toxicity in which 
copper accumulation results from failure o f normal liver transport into bile.
The identification of affected individuals within a known family is important to prevent irreversible 
neurological and/or hepatic damage. The determination o f serum and urine copper and of serum 
caeruloplasmin concentrations are usually but not always sufficient to make a diagnosis.
A dynamic test to assay the incorporation o f labelled Cu into serum caeruloplasmin may help 
diagnosis in equivocal cases. Tracer studies utilising the stable isotope 65Cu offers numerous 
practical advantages over the expensive and short-lived MCu (12hrs) and 67Cu (72hrs) 
radio-isotopes. A method for the determination o f 65Cu in serum has been established using 
inductively coupled plasma mass spectrometry (ICP-MS). The pattern o f 65Cu incorporation into 
the plasma protein pool o f normals, heterozygotes for the WD gene and cases at timed intervals 
after oral dosage has now been documented. Can these measurements be improved by isolation 
from plasma o f the main plasma Cu containing protein, caeruloplasmin ? Fast protein liquid 
chromatography (FPLC; Pharmacia) was employed to separate the main 65Cu containing plasma 
protein caeruloplasmin. Albumin was separated by gel filtration and affinity chromatography to 
varying degrees, subsequent advances in affinity media for Cp gave superior results.
Initially, four normal volunteers were given 65Cu orally, and had blood samples withdrawn at 
intervals up to one month. The fresh serum was prepared for ICP-MS analysis o f total 65Cu and 
caeruloplasmin bound copper isolated. This thesis describes the development o f methods to 
isolate the copper containing plasma protein caeruloplasmin labelled in vivo with 65Cu.
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ABBREVIATIONS
Alb-Cu - Albumin-Copper complex
Cp - Caeruloplasmin
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%En - percent enrichment 65Cu over 63Cu
PEG - Polyethylene glycol
PPD - para phenylene diamine
pH - acid to alkali scale 1-14
PBS - Phosphate Buffered Saline
pi - pH at which a protein has no net charge
rpm - revolutions per minute
s - seconds
pm - micrometre
pmol/L - micromoles per litre
Hg - micro gramme
w/v - weight by volume
INTRODUCTION
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This thesis is primarily concerned with the extracellular copper metabolism o f man in healthy 
people and in a particular disease state known as Wilson's disease (Brewer 1992). Central to the 
research work were attempts to isolate quantitatively and qualitatively the plasma protein 
caeruloplasmin (ferroxidase, iron I I : oxidoreductase)[EC 1.16.3.1], {he novel aspect o f the work 
being in vivo and in vitro experiments to label this protein with the stable isotope 65Cu. 
Caeruloplasmin (MW 132kDa) is the major copper protein in serum accounting for up to 95% of 
serum copper with the remainder associated with albumin (MW 67kDa) and low molecular weight 
amino acids such as histidine. A defect in caeruloplasmin is not the root cause o f Wilson's disease 
and people have been known to live indefinitely with no caeruloplasmin provided copper balance 
is achieved and maintained by other means. In fact, the gene for caeruloplasmin resides on 
chromosome 3 whereas the Wilson's disease gene is on chromosome 13. However, the question 
of copper balance in Wilson's disease cannot be addressed without consideration of 
caeruloplasmin's central role. Wilson's disease is characterised by failure to incorporate copper 
into caeruloplasmin in the liver, and failure to excrete copper from the liver into bile. The 
current understanding o f the molecular basis o f incorporation is that the Wilsons's disease gene 
produces the enzyme responsible for placing copper into caeruloplasmin. It is an ATPase o f the 
cell membrane which binds copper in the reduced (Cu+) state for which caeruloplasmin has an 
affinity. The route o f copper excretion may have a similar dependence on the redox state of 
copper. The importance o f this particular metal-binding ATPase is maintaining the copper ion 
in the reduced or cuprous state to allow incorporation into caeruloplasmin. Although much is 
known about the role o f copper in many essential enzymes and it's transport by plasma proteins 
the mechanism of transport between tissues is unresolved.
12
COPPER METABOLISM
The transition metal copper is an essential element required by all living systems. Classified as a 
"trace metal" copper is used by cells in the nanomolar range, but in micromolar concentrations 
may cause cell death (Shils 1991). Copper ions in living systems exist in two oxidation states: 
cuprous copper Cu+ and cupric copper Cu +. The cupric ion is an oxidising agent and blue in 
colour whereas the cuprous ion is colourless.
In man, copper ingested in the diet enters the gut and is first associated with albumin. Albumin has 
a single high affinity binding site for copper but readily donates this copper to the liver. (Linder et 
al. 1991, believe this function to be carried out by a high molecular weight protein designated 
"transcuprein" although this is not fully accepted). In the hepatocytes copper is associated with 
metallothionein. The liver functions as a store for copper from where it can be transported on 
caeruloplasmin to the tissues or excreted surplus to requirement as undegradable complexes in 
bile (Diag. 1). This prevents reabsorption in the gut and allows excess copper to leave the body 
via faeces at the approximate rate of 2X30^ daily. Urine represents a minor route of excretion 
with daily output o f 30-60pg copper. Small amounts are also lost in sweat, hair and nails.
The primary role o f copper is as a component o f the many intracellular copper metalloenzymes 
which perform various metabolic functions. Many cuproenzymes share a common biochemical 
principle by which molecular oxygen or a related species such as superoxide radicals are 
consumed. Cytochrome c oxidase governs the terminal reaction in mitochondrial oxidative 
phosphorylation. Lysyl oxidase is the key enzyme for the cross-linking reactions for collagen and 
elastin in connective tissues. Dopamine-P-hydroxylase metabolises catecholamines in the brain, 
superoxide dismutase is thought to provide antioxidant protection.
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Copper incorporated into caeruloplasmin and released into the bloodstream is free to donate its 
copper where the requirements of a cell provide the conditions of release (Diag. 2 after McArdle 
1992). Caeruloplasmin is also responsible for catalysing the oxidation o f ferrous (Fe++ ) to ferric 
(Ft* )  ions.
WILSON’S DISEASE
Wilson's disease is a rare (1:200,000) inborn error of metabolism that results in abnormal copper 
deposition in several organs. Excessive copper retention and toxic accumulation in the liver, 
kidney and basal ganglia of the brain leads to cirrhosis, renal tubular disorders and neurological 
damage. Characteristic biochemical findings are low serum copper <5pmol/l (ref. interval: 
12-24pmol/l ), increased urinary copper >2pmol/24hrs (ref. interval <lpmol/24hrs) and low 
caeruloplasmin concentrations (ref. interval: 200-500mg/l). Given positive indications from these 
tests a liver biopsy would be performed to determine the degree of copper accumulation, values of 
liver copper >250pgCu/g dry wt are significant. Wilson's disease is treatable to give normal 
lifespans when diagnosis is made at an early stage (Hiyamuta 1993). Treatment is by a variety of 
chelating agents that bind copper and allow excretion in urine, or by using zinc to block copper 
absorption in the gut. The gene for Wilsons's disease is located on chromosome 13 and closely 
linked markers can be used to follow the inheritance of the disease in affected kindreds. 
Restriction Fragment Length Polymorphism (RFLP) mapping uses markers on either side o f the 
gene (Gafthey 1992, Houwen 1993). This technique is slow and labour intensive also the distance 
of the markers from the gene makes "crossovers" possible. Presymptomatic diagnosis can be 
made more rapidly with Polymerase Chain Reaction (PCR) techniques using closer CA-repeat 
markers which are within a 300 kilo-base region o f the gene (Thomas 1994).
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The gene product proposed is a P-type ATPase, with six metal binding regions and this protein is
expressed in liver and kidney (Bull 1993, Petrukhin 1993, Tanzi 1993, Petrukhin 1994).
AIMS
(1) To determine the pattern of 65Cu incorporation into the plasma protein pool at 
timed intervals after oral dosage.
(2) To develop chromatographic separations of the main 65Cu containing plasma protein 
fractions at different times after oral dosage.
(3) To compare the time course of Cu isotope appearance in the serum of healthy controls 
with those of Wilson's disease kindreds.
(4) To examine the intestinal uptake and excretion of 65Cu in healthy controls and in 
patients with intestinal malabsorption.
CAERULOPLASMIN
17
Caeruloplasmin (Cp) is a single-chain a-2-glycoprotein o f 1,046 amino acids which binds up to 
95% of serum copper (Saenko 1994). The molecular weight is 132 kDa and this cleaves readily 
into three fragments of 67, 50 and 19 kDa by autolysis (Bonaccorsi de Patti 1992). The 
pronounced lability o f Cp has led to the hypothesis that these fragments could possess specific 
functions (Harris 1993). The protein contains 6-7 copper atoms in three distinct classes of copper 
binding site which are required for overall functional integrity. Type 1 is a mononuclear intensely 
blue site with an optical absorption at 610 nm. Type 2 or 'non-blue' copper has no visible 
absorption and Type 3 copper is likely to be made from two spin-coupled Cu^ ions absorbing 
weakly at 330nm (Calabrese 1989, Rylkov 1991).
BIOLOGICAL PROPERTIES
Caeruloplasmin possesses several primary functions as a copper transporter) as an enzyme 
(Holmberg 1951) and as a plasma antioxidant (Goldstein 1979, Sergeev 1993). Caeruloplasmin 
exhibits oxidase activity towards certain aromatic amines and phenols, cystine and ascorbic acid 
although the physiological significance o f this is not known. Caeruloplasmin controls ferrous iron 
oxidation, catalysing the incorporation o f absorbed Fet+ into the iron transport protein transferrin 
(Gutteridge 1993). Serum Cp levels rise in response to tissue injury, infection and inflammation 
as part of the acute-phase response, Cp levels doubling or tripling in the days following the event 
(Hansen 1988). The elevated total serum copper found in certain cancers was found to be due to 
Cp copper and independent of ultrafiltrable copper (Chan 1993).
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PREVIOUS ISOLATIONS
Caeruloplasmin was first isolated in 1948 by Holmberg and Laurell using salt and ethanol 
precipitation (Cohn fractionation). Subsequent developments in chromatographic methods 
established anion exchange as the principle technique for the separation and purification o f Cp. A 
crude DEAE cellulose column with sodium actate buffer was one o f the first methods to quantify 
Cp in health and disease (Deutsch 1960). A large-scale method succeeded in separating two forms 
of Cp from apocaeruloplasmin and degraded Cp. One hundred litres o f plasma was fractionated 
with polyethylene glycol (PEG 4000) and then further separated on DEAE-Sephacel (cellulose 
based), hydroxyapatite and Sephadex G-200 (dextran based) to produce a homogeneous protein 
with maximal enzymatic activity (Noyer 1980). A more modem method used DEAE-Sephadex 
and Sephadex G-200 to purify chicken Cp which is present at much lower concentrations than in 
man (Disilvestro 1985). The first use of FPLC employed DEAE-Sepharose and Superose 12 
(both agarose based) for the purification of rat Cp (Ryan 1992). The counter ion used for anion 
exchange is Cl' from sodium chloride. The buffers used vary. Mostly used are Tris-HCl and 
phosphate buffers including phosphate buffered saline (PBS). Acetate buffer is used for storage o f  
the separation products. Phosphate buffers are within the range pH 6.5-7.5 and acetate buffers 
pH 5-6. The stability o f isolated Cp is improved by cold storage in isotonic solution and adding 
protease inhibitors. The protease inhibitor epsilon-amino caproic acid (s-ACA) is used at a 20mM 
concentration.
FAST PROTEIN LIQUID CHROMATOGRAPHY (FPLC)
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The FPLC apparatus consists o f two calibrated pumps (P-500) controlled by a programmable 
gradient controller (G-250). A mixing chamber followed by a pre-filter is linked to a three-way 
valve. Attached to the three-way valve is a 10ml sample applicator (Superloop), the 
chromatography column and the waste bottle. The column outlet leads to an ultra violet monitor 
(UV-1), and from there to a carousel fraction collector (FRAC-1). A chart recorder traces the 
absorbance of eluent passing through a quartz cell at 280nm.
SAMPLE HANDLING
Freshly withdrawn blood samples in plain polypropylene tubes were allowed to clot for 15 
minutes. After centrifugation at 3,000 rpm for 15 minutes the clear yellow serum was removed 
with 1ml disposable pipettes. The protease inhibitor e-ACA was added as a 1M solution to give a 
final concentration of 20mM before storage at 4°C. Serum, prior to chromatography was diluted 
1:1 with buffer (1 X PBS + 20mM e-ACA) and passed through a 0.45pm filter (Millipore) fitted 
to a disposable syringe (Becton Dickinson). This was done to reduce the viscosity and ionic 
strength o f the sample and to remove any fibrin which may have formed.
The PBS buffer used was purchased as a single batch o f concentrate (Gibco; Paisley). After 
dilution with high purity water (Elgastat) and addition of e-ACA, the pH was 6.8 to 6.9. The 
buffer was prepared without calcium and magnesium to avoid ionic interactions.
Bacterial contamination was reduced by use of sterile plastic, such as polypropylene and 
single-use, non-bioadhesive filtration membranes (Nanosep, Amicon, Sherwood, Sterilin).
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MEASUREMENTS
The determination o f copper in serum and column fractions was performed by graphite furnace 
and flame atomic absorption spectrometry (Perkin Elmer, GBC) or by inductively coupled plasma 
atomic emission spectroscopy (Thermo Jarrel Ash ATOMSCAN25), (methods 5 and 6 
respectively). Spectrophotometers (Philips, Packard) were used to measure absorbance at 280 
and 610nm and the ratio 610/280nm used to gauge the purity of the isolated fractions. A ratio of 
0.045 or better, indicates that a sample contains 90% pure Cp. This was confirmed by high 
resolution electrophoresis (Sebia), (method 4). Spectrophotometry was also used to determine 
the specific oxidase activity o f Cp using as substrate, p-phenyldiamine (PPD), and measuring the 
rate o f formation o f the purple oxidised product (method 12). Immunological reactivity was 
assessed using immunodiffusion with polyclonal antibodies (Behring), (method 7).
GEL FILTRATION
21
INTRODUCTION
Gel filtration is a technique for the separation o f proteins according to size. The gel is comprised 
of porous beads, packed into a chromatography column, through which a liquid phase is pumped. 
The separation depends on the different abilities o f the proteins to enter and leave the pores within 
the beads. The largest proteins cannot enter even the biggest pores and hence pass through the 
column fastest and are eluted first. Smaller proteins enter the pores to different degrees depending 
on their size and shape, while the smallest proteins are retarded by the labyrinth o f channels in the 
gel and elute last. The best resolution is achieved using a small sample applied to a long column at 
a slow flow rate.
MEDIA SELECTION
The copper containing plasma proteins are best separated with a gel having a range o f pore sizes 
which encompass the entire fractionation range o f the (more than a hundred) serum proteins. 
Sephacryl 300HR (Pharmacia) fits this criteria with a fractionation range o f 10 -l,500kDa. 
Sephacryl also has the high mechanical strength necessary to support a long column without 
causing compression o f the gel bed. The composite gel is made by covalently cross-linking allyl 
dextran with N,Nf-methylene bisacrylamide. It is the dextran component which contributes to the 
porosity of the gel and hence its fractionation range. The gel is supplied pre-swollen with a wet 
bead diameter o f 25-75p.m in a slurry of 20% ethanol.
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RUN CONDITIONS
When the gel is packed into a lm  long column with 200mM Tris-HCl pH 7.4 as the liquid phase the 
conditions are optimal for a l-2ml serum sample. A sample is run at 0.5ml/min for 14 hrs with the 
collection of one hundred 4ml fractions (Gardiner 1982). Protein concentration is measured as the 
absorbance of the solution at 280mm in a quartz cuvette (Graph 1). Copper is determined in each 
fraction by electrothermal (carbon furnace) atomic absorption spectrometry (see method 5) and 
albumin by immunoturbidity (Centrifichem, Atlantic Antibodies) (Graphs 2, 3). Attempts to 
measure caeruloplasmin by the same method were unsuccessful because large dilutions o f the 
serum sample made the concentration of this protein undetectable by these means.
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RESULTS AND DISCUSSION
This method gives some information as to the distribution of Cu among the serum proteins. 
Copper is seen to be localised in two distinct fractions with a higher and lower copper content. 
These fractions can in turn be shown to cross-react with caeruloplasmin and albumin antibodies. 
This agrees with previous observations that up to 95% of serum copper is bound to 
caeruloplasmin and a smaller percentage, less than 5% to albumin. In gel filtration experiments it 
is generally assumed that complete separation occurs where the molecular weight o f two proteins 
differ by a factor o f two, and that one is about twice the size o f the other. The molecular weights 
of Cp;132kDa and Alb; 67kDa fulfil this theoretical requirement but as graphs 2 and 3 show, the 
actual separation is not complete and takes considerable times even for a small sample volume. 
The application of this system to the separation o f albumin at an average o f 40-80 g/1 in serum and 
of Cp at an average 0.3 g/1 is not feasible if we wish to quantify 65Cu uptake by these proteins. 
The dilution factor of 1:400 makes it difficult to measure the concentration o f caeruloplasmin by 
immunoturbidity.
27
ION EXCHANGE
Gel filtration cannot separate albumin from Cp with the necessary resolution. Caeruloplasmin 
because o f its lability, needs to be separated rapidly to preserve its structural integrity (Dwulet 
1981, Gutteridge 1985). The average concentration of Cp in human serum is 0.3g/l (Gibbs 1979, 
Louro 1989). To have enough Cp to measure at normal concentrations and those with lowered 
levels at least one to five mis of serum is required. The serum sample is stabilised with the 
protease inhibitor (8 -AC A) and diluted 1:1 with buffer ( I X  PBS). The dilution reduces the 
viscosity o f the sample and adjusts the ionic strength to a level suitable for ion exchange.
PROCEDURE
The basis for optimising any chromatographic scheme are considerations o f speed, capacity, 
resolution and recovery. Media for ion exchange give high flow rates, high affinity protein binding 
and allow the application o f a relatively large sample compared to the column volume. Ion 
exchange separates proteins according to differences in electrostatic charge and is highly selective. 
The charge of a protein is characterised by it's isoelectric point (pi) which is the pH at which it 
carries no net charge.
When at a pH below its pi the protein will carry a positive charge and at a pH above it's pi it will 
carry a negative charge. The pi determines whether a positively charged exchange media (an 
anion exchanger) or a negatively charged media (a cation exchanger) is used. The pH of the buffer 
determines the charge on the proteins and the extent to which they bind to or pass through the 
media. For proteins such as albumin and Cp with pi's o f 4.9 and 4.4 respectively, a pH o f at least 
one unit above the pi will ensure a sufficient charge on the proteins to allow a weak anion 
exchanger to be used.
28
SEPHAROSE
The ideal gel must have good stability to allow the high flow rates needed for rapid separations. 
Such a gel is DEAE-Sepharose Fast Flow (Pharmacia) based on agarose beads with 45- 165pm 
diameter. The exchange group di-ethylaminoethyl (DEAE) is attached to a bead structure o f 6% 
highly cross-linked agarose by stable ether linkages. The resulting structure is macroporous with 
good capacity for proteins of 1-1000 kDa, has excellent flow properties and low non-specific 
adsorption of proteins.
CONDITIONS
Ion exchange separates the components of samples carrying different net charges of varying 
strengths. Anion exchange uses a gel bearing a positive charge (DEAE) to which proteins 
carrying the opposite net charge to the gel bind by electrostatic forces. The charge o f the gel is 
manipulated with the use o f a counter ion, in this case, chloride (Cl ). Proteins are then displaced 
and selectively eluted from the column with an increasing salt gradient. The greatest degree o f  
fractionation is obtained when the protein of interest binds to the column and other molecules 
pass through. This involves the use o f two buffers, the first a 'running' buffer and the second an 
'elution' buffer. The running buffer (lxPBS + 20mM S-ACA) carries the majority o f the sample 
through the column unbound. The elution buffer (lxPBS, 0.5M NaCl + 20mM S-ACA) charges 
the column with chloride counter-ions before equilibration with running buffer. Elution buffer is 
then used either by increasing the salt gradient to selectively remove more strongly attached 
proteins or in a single step to concentrate all proteins displaced by the NaCl content o f the elution 
buffer. Stronger (2M) NaCl solutions are used to remove other ionically bound proteins and 1M 
NaOH to remove precipitated proteins and lipoproteins. To limit contamination a periodic, "trace 
metal" removal with 200mM EDTA, is part o f the normal procedure (method 13). The diluted 
serum sample is applied at lml/min to a 1.7 x 20cm column packed with DEAE- Sepharose Fast 
Flow at room temperature to give the chromatogram (Diag3).
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The peak containing Cp is eluted in a single step in elution buffer a volume of 10-15mls. After 
concentration (method 8 ) of the peak fractions, the absorbance at 280 and 610nm is used to 
gauge the purity o f the separated Cp (method 2).
OTHER METHODS
31
In addition to ion exchange and gel filtration two other methods o f isolating caeruloplasmin were 
investigated. These remove major serum proteins thereby simplifying the separation. The first 
involves the precipitation high MW proteins with polyethylene glycol (PEG). The second uses 
affinity chromatography to selectively retain albumin, and separate it from Cp.
PEG PRECIPITATION
Polyethylene glycol is a polymer that binds proteins having a suitable surface for adhesion. It also 
has the useful property o f stabilising Cp in solution without the use o f e-ACA which is potentially 
toxic.
PEG, MW 4000, is made up in water or buffer as a 40% w/v solution. This was mixed 1:1 with 
serum samples to give a fraction containing Cp. After precipitation overnight in the cold room 
(4-10°C) samples are centrifuged for 15mins at 3,000rpm in a benchtop centrifuge. The 
supernatant is then recovered for further purification.
The procedure is mild and does not affect enzymatic activity. It is a most useful step in the large 
scale isolation of undegraded Cp from "outdated" human serum (Oostuizen 1985).
AFFINITY CHROMATOGRAPHY FOR ALBUMIN
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Affinity chromatography is a type of adsorption chromatography in which the molecule to be 
purified is specifically and reversibly bound to a ligand attached to the gel matrix which has 
affinity for a group of proteins which share a common binding site. The ligand used is a dye, 
Cibacron Blue 3G-A, covalently attached to the highly cross linked agarose gel Sepharose CL-6B 
(Pharmacia). The dye binds a variety of proteins including coagulation factors, interferon and 
albumin. The mechanism of the molecular interaction is well documented (Gianazza 1982, Amaud 
1982). Some proteins interact biospecifically, such as albumin and interferon, whereas other 
proteins (such as Cp) bind in a less specific manner by electrostatic or hydrophobic attraction. The 
critical parameters of pH, ionic strength and temperature determine the extent of binding.
The separation o f Alb from Cp is carried out at near the physiological pH and at room 
temperature. Serum samples (l-3mls) are diluted 1:1 with buffer (PBS pH 6.9 ) to reduce 
viscosity and adjust pH. The sample is then applied at 2mls/min to a 5ml TliTrap Blue' column 
(Pharmacia). Cp is bound to the column though not as strongly as Alb. Cp can be then eluted with 
PBS containing 650mM NaCl while albumin remains bound. Finally, albumin is desorbed with 
0.5M NaCNS, but it’s copper remains attached to the column.
The application of affinity chromatography with Blue Sepharose to the separation o f Alb from Cp 
is feasible. However, it requires the use o f three buffers which makes the processing o f multiple 
serum samples time consuming and reproducible separations are difficult to achieve.
STABLE ISOTOPE STUDIES
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To study the kinetics of copper absorption, it £ tissue distribution and excretion requires the use of 
oral and/or intravenously administered copper tracers. Radioactive tracers are relatively easy to 
measure but the half-lives of the copper isotopes are short and the radiation dosage unacceptable 
for pregnant women and for children. There are two copper radio-isotopes that can be used, ^Cu 
(half-life 12.9hrs) and 67Cu (half-life 61.9hrs). They do not allow long term metabolic studies. This 
has resulted in good definition of copper distribution in the first few days and hours following 
administration but not during the following weeks.
Copper has two stable isotopes 63Cu and 65Cu with natural abundance's o f 69.09% and 30.91% 
respectively. The use o f stable isotopes depends on an accurate measurement o f  the 65Cu : 63Cu 
ratio in serum, now possible by ICP-MS (Lyon 1990). The proportion o f 65Cu in serum is 
increased by giving 65Cu orally. Dosages for adults o f 3 mg, irrespective of body size are given. 
This produces an in vivo enrichment o f the less abundant 65Cu in serum samples taken at various 
times after the dose. The enrichments can then be followed until the absorbed 65Cu disappears 
from the circulating blood serum and is excreted. The pattern of 65Cu serum enrichment over days 
or weeks can be used to examine copper handling in both health and disease.
ICP-MS EQUIPMENT
The machine used was a Plasmaquad PQ2+ ICP-MS (VG-Elemental: Fisons). The ions for mass 
analysis are produced conveniently from liquid samples by the inductively coupled argon plasma 
(ICP) (Diag.4). The singly charged Cu+ analyte ions generated in the ICP are extracted into and /
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and/ measured with a quadropole mass spectrometer (Diag.5). The liquid sample is pumped along 
plastic tubing by a peristaltic pump to the nebulizer. This converts the liquid sample into an 
aerosol before introduction into the ICP spray chamber. The nebuliser used was a "Mienhard" 
concentric nebuliser which exhibits good long term stability, but because of the very small annular 
gap is prone to blockage by particles in the analyte solution and by solutions having high solute 
concentrations. The sample is thereby contained in a laminar flow of argon which is introduced to 
the ICP torch. A "Fassel" torch is used, consisting of three concentric silica tubes with tangential 
gas entries to the outer and intermediate tubes. Aerosol is introduced through the small-diameter 
tube along the torch axis. This "injector” inner tube has a constricted exit at a distance from the 
end o f the outer tube and coinciding with end o f the intermediate tube. The end of the outer tube 
is encircled by three turns of copper coil through which a high current generated by a 
crystal-controlled radio frequency of 27.1MHz is passed to form the plasma. The plasma is an 
ionised gas with high excitation, ionisation and electron temperatures. The high temperature 
region of the plasma exists as Ar + e' <-» Ar+ + 2e' providing metastable (Ar1^ ) and charged (Ar+) 
ions by "Penning ionization" and "Charge transfer" respectively, ft is self-sustaining after initial 
seeding with a few electrons from a*Esla coil. The sample in its carrier gas stream is injected into 
the high temperature atmospheric pressure argon plasma where it is desolvated, atomised 
(excited) and ionised. The central portion of the annular plasma is extracted into a low pressure 
region (10'2 Torr, maintained by rotary vacuum) through the sample cone. The plasma material is 
transported as a supersonic jet, a small proportion (1-3%) of which passes through the skimmer 
cone orifice. Positive ions are extracted and focused by an ion lens system into the quadropole 
mass filter and filtered according to their mass to charge ratio. Individual ions are detected by an 
ion counting electron multiplier known as a "channeltron" counter.
ION
 
FO
CU
S 
IN
G
Diag 5 36
c
o
Vo
o .
a .
C/5
C/5<D
VoDo
GO T 3
\
\
£  Do 
§  6
8 1  
>  a
vo
C/5
SS<+o
B
33Ocj
>
6
B
CN
CX.
63Do
, t>0 V G
•  f-HIX)
3
H
N
t:cd
3a
37
The channeltron can operate at high beam currents in analogue mode. The horn shaped channel 
o f the counter is made of made of glass with a resistive surface. This device can be thought o f as a 
physical charge amplifier. Impacting ions release secondary electrons. These undergo further 
collisions with the tube walls, releasing more electrons, and an exponential avalanche builds up 
down the channel giving a gain o f around 108.
SAMPLE REQUIREMENTS
The direct measurement o f the 65Cu/63Cu ratio is not possible in whole serum because of 
polyatomic interference. Sodium and argon ions combine to give a product Na-Ar+ with the same 
mass as 63Cu. The observed ratio is not accurate and the serum sample must be desalted to 
separate Cu from Na (method 1). The protein moieties also introduce polyatomic interference, 
from sulphur 32S-33S . Addition o f concentrated nitric acid (20|il per ml (2%)) ensures that proteins 
are precipitated and sulphur removed while the Cu stays in solution. Samples were then made up 
to lOmls in deionised water and the Cu concentration determined by flame AAS (method 6). 
Subsequent dilution with 2% nitric acid to < 0.3pmol/Cu/L ensured that the channeltron 
operated only in pulse counting mode. Too high a Cu concentration results in the channeltron 
switching to analogue mode which is not desirable during pulse counting.
Samples that were stored in the cold room required centrifugation (15mins at 3,000rpm) 
immediately before analysis to remove any precipitate or particulate matter.
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RUN CONDITIONS
Samples were presented to the instrument in a volume of lOmls and five replicate measurements 
of the 65/63Cu ratio made over five minutes (method 11). A blank and five standards were run 
before the samples to ensure consistent measurement at the start o f the run and give the baseline 
for mass bias correction. A standard was included after every five samples for mass bias 
correction. Printouts give actual counts (blank corrected) for 63Cu and 65Cu ions for the five 
readings with a mean and standard deviation (%SD). An acceptable imprecision is < 0.5%.
MASS BIAS CORRECTION
The blank corrected 65/63Cu ratio produced by the ICP-MS requires correction for mass bias. This 
is the tendency of the instrument to overmeasure or undermeasure the known ratio o f the standard 
solution, determined by the measurement o f the five initial standards. As the 65Cu atom is heavier 
than 63Cu, it is subjected to stronger forces on passing through the quadropole focusing field. The 
natural ratio is obscured by this artefact. Correction is made to the blank corrected ratio 
(automatically calculated) by multiplication with a discrimination factor (f). This factor is worked 
out by taking the natural 65/63Cu ratio (0.4474) and dividing it by the mean ratio of the five 
standards. The amount of mass bias occurring between control points is added or subtracted in a 
linear fashion according to the direction of the bias. The 'f factor is then used to multiply the 
blank corrected 65Cu/63Cu ratio obtained to give the true ratio. This may occur for any number of  
reasons, such as time o f day (other instruments being turned on and off) or duration of operation. 
Although the instrument may not measure the same ratio on a sample with a known 65/63Cu ratio 
the control samples allow for correction o f any difference.
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The percent enrichment (En%) is worked out by subtraction of the natural ratio from the 
measured ratio as a percentage of the natural ratio by the following formula;
65Cu/63 corrected - Cu65/63 natural 
%En = ________________________________  X 100
65Cu/63 natural
^Cu RESULTS
The results o f radio active studies performed in the 1960's (Diag.6 after Stemlieb) first elucidated 
the picture o f copper turnover. It was seen that one or two hours after ingestion radio active Cu 
appears in the circulating blood plasma as a sharp peak over 1-2 hours subsiding to a trough at 
about six hours. There is then a gradual reappearance o f radioactivity (cpm) reaching a maximum 
after seventy-two hours. The initial peak is produced as some of the copper on albumin 
transported from the gut via the hepatic portal vein bypasses the liver at the first pass and enters 
the peripheral blood. The secondary rise occurs after copper incorporation into caeruloplasmin. 
Taking the ratio for the secondary rise to the initial peak should give a value greater than one for 
normals and less than one for failure to incorporate into Cp and retention by the liver. The ratio of 
the initial peak to the trough was used to show the clearance and reappearance effect absent in 
individuals with disorders o f Cu incorporation into Cp.
Cu
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Stable isotope investigations have now been carried out on fifteen normals (Graph 4) and eight 
WD patients (Graph 5). The shape of the graphs are similar to those obtained by radioactive 
copper. The initial rise at l-2hrs is present in both graphs but the secondary rise, as 65Cu appears 
on caeruloplasmin, is shown by normal subjects and is absent in WD patients. When expressed as 
ratios, the 72/2 hour ratio is greater than 0.5 in normals and less than 0.5 in affected individuals. 
The 72/6 hour ratio is greater than 1.5 in normals and considerably less in WD cases (0.15+/-0.06 
n=7). These ratios are o f diagnostic importance in equivocal cases (Lyon 1995).
The stability o f the isotope offers other possibilities, in that the ability to follow 65Cu over a longer 
course o f time, allows the estimation of the biological half-time (t]/2) o f copper in serum. The four 
subjects studied; L.W., B.S., S.M. and P.G., have half-times of 27, 27, 17 and 21 days 
respectively, with an average of 23 days.
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THE METABOLIC STUDY
A study of copper metabolism using the stable isotope was designed (method 14), which involved 
measurement of 65Cu enrichment in whole serum, caeruloplasmin, urine and faeces. The biological 
half-time o f copper can be calculated, and the 65Cu enrichment of faecal excreta allows calculation 
of Cu retention (Diags 7, 8, 9, 10). For this calculation it is important that all the plastic pellets 
given as markers are recovered. The pellets are made of a radio-opaque material and can be 
counted in the faecal samples by X-ray. Five consecutive collections are made on the five days 
after the 65Cu dose. The retention o f the given dose in four normal subjects after five days was 
from 42.2 - 54.6%. This indicates that over the given time, around half the 65Cu is excreted by the 
normal subject.
Four volunteers, two male and two female provided an average o f fifteen blood samples o f lOmls 
each at frequent intervals over five weeks (Diags 11,12). The serum was split into portions, 2.5mls for 
total serum Cu and the remainder (usually 1-3mis) for Cp isolation. Samples for total serum 65Cu 
were prepared for IGP-MS by gel filtration (method 1). Cp isolation was performed as follows:
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FPLC Isolation Procedure
1) l-3mls serum + 20mM s-ACA (protease inhibitor).
2) Dilute 1:1 with start buffer to reduce viscosity and ionic strength.
3) Filter through 0.45pm filter to remove particulate matter.
4) Bind Cp to DEAE-Sepharose FF allowing most other proteins to pass through
The column is run at 2ml/min with 1 X PBS pH 6.8 as the buffer.
5) Elute the bound Cp stepwise or with a salt gradient increasing to 
650mM NaCl concentration.
6) Read absorbance of eluted fractions at 280 and 610nm (method 2).
7) Pool, concentrate and desalt fractions with 610/280nm absorbance ratios > 0.02.
8) Sample further purified on Mono Q column or by gel filtration on Superdex 200HR
9) Cp peak collected and measured by immunodiffusion (Behring).
10) Fast desalting and buffer removal on Sephadex G25 (superfine).
11) Precipitation of proteins with lOOpl/ml conc. nitric acid.
12) Centrifuge at 3,500rpm for 15mins.
13) Make up to lOmls with deionised water (sample for ICP-MS).
14) Measure copper concentration on GBC-Flame AA ( method 6).
Care must be taken at each stage to minimise sample losses on filters and containers, limit the 
introduction o f air bubbles into columns and prevent contamination. The procedure takes time in 
particular the initial separation on DEAE sepharose which improves with slower runs and larger 
samples. The average is 45mins per sample. A number of runs may be completed before it is
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necessary to clean the column, by washing with NaCl, NaOH and EDTA successively (method
13).
A freshly poured column was used for each volunteer. The elution of Cp with NaCl was found to 
be effective at a minimal concentration of 650mM. This is still high enough to Induce a rapid 
breakdown of the molecule after elution so it is important to remove the salt before storage 
(method 8).
COPPER RECOVERY
Copper recovery is a measure of the efficiency of the separation since 95% of Cu is Cp bound. 
An initial total serum Cu measurement was made on a fresh serum sample by the routine 
analytical procedure which had satisfactory bias and imprecision in national QC schemes.
The results were as follows;
Volunteer Serum Cu (fimol/L) Reference Interval
L.W. (Male) 15.0 12-24pmol/L
B.S. (Female) 17.5
S.M.(Female) 26.5
P.G. (Male) 12.5
Fractions eluted during sample runs not being used in subsequent separations were measured to 
ensure that they contained no more than O.lpmol/L Cu before disposal. Fractions eluted during 
column cleaning with 200mM EDTA (a strong Cu chelator) were measured to account for Cu 
removed from albumin during chromatography on DEAE Sepharose. The copper in the samples 
prepared for ICP-MS was measured by flame AAS (Diag. 11).
Diag 11
COPPER IN ICP-M S! PREPARATIONS
(fxmol/Cu/L)
L.W. B.S. S.M. P.G.
T=0hrs 1.3 2.6 4.4 1.3
T=0.5hrs 2.6 4.3 7.5 0.6
T=1.5hrs 2.8 4.8 4.1 0.1
T=2hrs 1.8 5.1 2.1 0.1
T=2.5hrs 1.3 5.5 5.4 1.7
T=6.5hrs 2.2 5.9 6.4 1.9
T=24hrs 2.5 4.2 5.2 0.1
T=48hrs 0.1 4.2 4.3 1.6
T=72hrs 2.5 6.4 4.1 2.2
T=96hrs 2.3 2.6 6.9 1.9
T=lwk 3.5 3.1 9.8 1.5
T=2wk 2.6 3.6 4.9 2.6
T=3wk 3.5 3.7 3.7 1.2
T=4wk 2.2 4.3 2.9 0.8
T=5wk 0.6
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An estimate of copper recovery from the FPLC column was made on the first serum sample from 
each subject.
Recovery was calculated as;
Cu concentration in Volume of
pooled Cp fractions x pool
 ( p m o l / 1 ) ___________________  (D
Serum Cu concentration x Volume o f
(]Limoi/l) serum used (1)
Recoveries from the initial serum samples were as follows;
L.W. 74.3%
B.S. 81.9%
S.M. 81.8%
P.G. 50.4%
CAERULOPLASMIN RECOVERY
Initial Cp values were obtained by nephelometry because o f the QC (see p. 50) on this 
measurement. The following values were obtained;
Volunteer Value Reference Interval
L.W. 254mg/l 200-500mg/l
B.S. 280mg/l
S.M. 474mg/l
P.G. 194mg/l
Caeruloplasmin was also measured by a single radial immunodiffusion (Behring) o f 5pi from the 
concentrated product before desalting and buffer removal. The purity o f the preparation was
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gauged by spectrometry. Caeruloplasmin purity and recovery was calculated as shown in the 
following example;
L.W. - 254mg/l = 0.254 mg/ml x 2mls (volume of serum sample) = 0.509mg 
- 0.509mg Cp present in initial sample.
Immunodiffusion plate results; 610/280nm Absorbance ratio;
1. T=0hrs - 0.033
2. T=0.5h 592mg/l 0.025
3. T=1.5 613mg/l 0.027
4. T=2 254mg/l 0.060
5. T=2.5 350mg/l 0.040
6. T=6.5 552mg/l 0.064
7. T=24 720mg/l 0.025
8. T=48 317mg/l 0.024
9. T=72 384mg/l 0.017
10. T=96 333mg/l 0.034
11. T1WK 592mg/l 0.039
12. T2WK 419me/l
Total = 5136ma/l / 12 = 428ma/l
0.031
Average percentage recovery ; 428mg/l = 0.428mg/ml x 1ml (volume o f conc..
fractions ) = 0.428 mg 
- 0.428/0.509 x 100 = 84.1%
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Results
L.W. 84.1%
B.S. >90% ) Beyond limits of
S.M. >90% ) immunodiffusion plate. (Later found to be out of date)
P.G. 27.3% (This was due to overwashing the column with EDTA.)
ICP-MS RESULTS
The Cp isolated from the four subjects, was prepared for measurement o f isotopic enrichment by 
ICP-MS (Diag.12). Results are presented as graphs on the following pages. The %En values are 
considerably lower for Cp than expected due to loss of copper during chromatography. This was 
investigated as follows:
CAERULOPLASMIN INCUBATION WITH 65CU
It has been shown that it is possible to label caeruloplasmin with radioactive copper by exchanging 
a portion of the copper atoms in vitro under reducing conditions (Scheinberg 1957, Stemlieb 
1961). The amount o f copper incorporated is reported as 35-50% o f total Cp copper. The 
exchange involves the shuttling o f the copper atom between monovalent and divalent states under 
reducing conditions.
I found that the incorporation in vivo of 65Cu into caeruloplasmin was at a lower level than 
expected. If this was due to an experimental artefact then solutions of Cp which had exchanged a 
portion of the natural copper for 65Cu should show the difference before and after passing 
through the separation procedure.
Diag.12 55
65Cu PERCENTAGE ENRICHMENT IN FOUR METABOLIC SUBJECTS
Time hrs. L.W. Tot L.W. Cp B.S. Tot. B.S. Cp S.M. Tot. S.M. Cp P.G.Tot. P.G. Cp
0 0 0 0 0 0 0 0 0
0.5 7.69 0 6.73 0 1.18 0 3.57 0
1.5 11.42 0 6.79 0.78 7.24 0 11.66 0
2 10.37 0.07 5.52 0.96 7.26 1.62 8.14 0
2.5 8.76 1.22 4.36 1.16 7.55 2.01 6.5 0.17
6.5 4.83 1.45 3.22 - 6.93 3.1 2.32 -
24 5.96 2.63 4.4 1.74 11.42 6,34 3.78 0.68
48 7.19 - 5.92 2.08 13.52 7.41 5.25 3.22
72 7.11 3.98 6.84 2.32 13.75 8.36 5.39 4.01
96 7.55 4.38 7.48 4.27 14.26 9.65 6.13 4.16
lwk:144 7.35 6.12 7.73 5.6 12.62 9.4 7.59 4.43
2wk:168 7.19 3.88 7.77 5.54 10.23 8.18 6.53 5.14
3wk:336 6.08 - 7.73 5.45 7.8 4.12 4.8 3.75
4wk:504 5.49 2.87 - - 5.81 0.9 4.12 2.21
5wk:672 - - 4.74 - - - - 1.54
Key;
Tot. = Percent Enrichment in whole serum.
Cp. = Percent Enrichment on isolated caeruloplasmin.
0 = Measured as 0.
- -  Sample not collected or lost in process o f separation.
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Experimental conditions
1) Materials
- 65mmol/L 65Cu++ nitrate in nitric acid
- lOOmM sodium acetate buffer pH 5.5
- Saline 0.9%
- 1M L-ascorbic acid
- Purified caeruloplasmin lmg in 22 pis
2) Volumes
- 2.5mls for PD-10
- lOmls for ICP-MS
3) Conditions
The success of the label is critically dependant upon time, temperature, 
concentration o f substrate and reductant added, pH and ionic composition 
of labelling mix.
- Temperature 37°C
- Time 1.5hrs under vacuum 
-pH  = 5.4
- Caeruloplasmin 0.3mg/ml
- 25mM L-ascorbic acid
- 20mM e-amino caproic acid
Both commercial (Sigma) and FPLC purified Cp were incubated under the conditions described. 
Chelex 100 was used to remove loosely bound Cu (method 9) from all samples. Half were then
6 1
directly prepared for ICP-MS while the others were put through the FPLC procedure before 
being prepared for ICP-MS measurement. A trial incubation was carried out without vacuum and 
demonstrated the feasibility of labelling. Incubations were then performed for commercial and 
FPLC- isolated Cp.
Samples were prepared in triplicate with controls for both copper and caeruloplasmin. The 
experiment was conducted under vacuum with, ascorbic acid as the sole reducing agent. The 
enrichment o f caeruloplasmin with 65Cu was 135% on average after removal of the ascorbic acid 
and excess ionic copper. After subjecting the caeruloplasmin sample to FPLC chromatography 
the enrichment fell to 94%En representing a 70% recovery of immunologically active protein. 
Since only caeruloplasmin was applied to the separation procedure the copper loss can be directly 
attributed to the chromatographic process. Ionic copper can therefore be exchanged with active 
caeruloplasmin to a significant extent.
Commercial Cp Results
% Enrichment (see p.39)
1) Reaction buffer + caeruloplasmin 0.04
2) " + 65Cu 0.00
3) Buffer, ascorbic acid , 65Cu and Cp 134.43
4) " 135.12
5) " 135.62
6) Buffer, ascorbic acid, 65Cu and Cp post FPLC 88.98
7) " 98.16
8) " 94.69
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FPLC Isolated Caeruloplasmin
Caeruloplasmin was isolated as described from standard male serum (method 16) to give the 
following percent enrichments after incubation.
Cu (umol/L) %En Procedure
1) 5.9 204 PD-10 into water
2) 5.3 205 If
3) 6.8 208 1
4) 5.0 134 post-FPLC
5) 6.4 145 ll
6) 7.4 135 II
The mean %En ex-FPLC = 205. Mean %En post-FPLC = 138. This gives a 33% loss of 
enrichment following chromatographic separation. Two points are notable, first that %En is 
independent o f Cu concentration and secondly that there is less than 2% variation in the degree of  
exchange. Despite higher enrichments on the FPLC isolated Cp and different degrees of labelling, 
the results conclusively demonstrate a consistent loss o f approximately 30%En post-FPLC.
APPLICATION TO WD KINDREDS
The application o f FPLC isolation of Cp in Wilson's Disease kindred's was investigated. The 
subjects studied were heterozygotes or unaffected. WD cases have a low total serum Cu and Cp 
and do not incorporate 65Cu effectively, preventing their study by this procedure. The first subject,
S.A., an unaffected female with two affected brothers showed a normal enrichment (Graph 10)
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with levels similar to S.M. in the metabolic study. She was followed over a four week period with 
blood samples withdrawn at 0, 1, 2, 4, 6, 72 hrs and 1, 2, 3 and 4 weeks. The other subjects are 
three obligate heterozygotes from the same family sampled at 1, 2, 3 and 4 weeks after oral 
dosage (Graphs 11,12,13). As we would expect, the enrichments are lower than the values 
obtained for normals in the metabolic study. An interesting observation is the later occurrence of 
a peak in Cp enrichments. In the four normals this is one week after ingestion of 65Cu whereas the 
three heterozygotes have peak enrichments two or three weeks after the dose. This may be 
indicative of a slower or partially defective mechanism for handling copper in those who do not 
develop the full-blown disease.
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AFFINITY CHROMATOGRAPHY FOR CAERULOPLASMIN
TENTACLE SEPHAROSE
A chromatographic media with a particular affinity for caeruloplasmin was first described in Italy 
(Calabrese et al 1988). The group produced a derivative o f Sepharose 4B by reaction with 
chloroethylamine. The resulting polyethylenimine is a branched polymer with an amine group 
distribution o f 25% primary, 50% secondary and 25% tertiary. This has the property of selectively 
binding caeruloplasmin, and only a few other proteins.
Calabrese et al were interested in the electroparamagnetic (EPR) properties o f the three distinct 
classes o f copper-binding sites in caeruloplasmin. Type 1 copper occupies a mononuclear 
intensely blue site and the type 3, binuclear site is EPR-undetectable because o f magnetic pairing. 
Type 2 is the most important for EPR studies. However, conventionally isolated Cp undergoes 
conformational changes leading to irreversible modifications in EPR spectroscopy. To visualise 
the copper in its natural state required the isolation o f Cp by a rapid and single-step procedure. 
This allowed the demonstration of a dramatic change in the EPR copper signal due to 
physiological aging. The EPR signal for Cp-copper was stable for individuals up to 65 years old 
and then increased two-fold in older subjects. It is well known that modifications of protein 
structure occur during growth and development, but that further changes occur in ageing was 
previously unobserved.
I used the tentacle gel to follow the enrichment of albumin with 65Cu, in addition to total serum 
and caeruloplasmin enrichments. This was previously prevented by the removal o f Cu from 
albumin by the DEAE gel, during the FPLC seperations.
The 'tentacle gel' used is as prepared by the Italian group as follows;
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Sepharose 4B (Pharmacia) in a 300ml gel bed suspended in 100ml o f 5M NaOH, was treated with
epichlorohydrine (25mls) at 70°C for two hours, and then, after washing with 10M NaOH, with
130mls of chloroethylamine at 70°C for two hours. A pH of 9-10 was maintained by addition of
10M NaOH. The derivatized Sepharose 4B was thoroughly washed with distilled water and
equilibrated with 30mM phosphate buffer pH6.8 .
USE OF 'TENTACLE GEL'
1. All operations should be carried out in a cold room at 4°C.
2. Load 1 to 2mls o f the gel slurry onto a column (0.5 cm x 20 cm) and let it sediment.
This takes about 30mins. Note; The gel is not stable enough to withstand applied 
pressure from a pump and is run under gravity.
3. Wash the gel using two bed-volumes o f NaOH (lOOmM). This will eliminate bacterial 
growth and protease activity. Then wash with deionized water to neutral pH.
4. Wash with two bed-volumes o f MES (morpholinethanolsulphonic acid) 150mM, pH 6.7
5. Load the gel with 4ml o f plasma or serum adjusted to pH 7.4
6. A blue band appears on top of the gel column.
7. Wash with MES buffer to eliminate traces of albumin. Monitor UV absorbance at 
280nm.
8. Elute Cp using di-sodium phosphate buffer (pH 7.2),(300 - 500mM).
9. The column can be reused, after washing with NaOH. One ml bed volume can be used 
for 20ml serum or plasma.
70
TOTAL SERUM COPPER RECOVERIES
The copper recovered after separation of 2.5mls serum on tentacle gel was as follows:
Serum pool 
(50mls)
Serum Cu 
(pmol/l)
Cu cone, of isolated Cp 
(jimol/1)
% Recovery
A 24 23 96
B 20 19 95
C 20 18 90
D 22 20 91
E 15 13 86
F 21 20 95
G 23 20 86
Average 91
RECOVERY OF CAERULOPLASMIN 
(measured by immunodiffusion)
Serum pool Cp value After %  Recovery
(SOmls) (mg/1) separation
A 513 493 96
B 456 437 96
Four controls and one patient with malabsorption have been investigated using this 
separation procedure. Blood samples were withdrawn at 1, 2, 6 and 72 hours after ingestion of
3 mg 65Cu. The serum was separated and preserved with 20mM 8- AC A. Half the serum was used 
for total serum copper measurement. The remainder was separated on tentacle gel columns to 
isolate albumin and caeruloplasmin copper. The samples were prepared for ICP-MS measurement 
in the usual way. Results are shown in Graphs 14,15,16,17 and 18:-
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DISCUSSION
The four controls show the previously observed pattern of 65Cu enrichment in total serum and 
caeruloplasmin copper. Enrichment o f albumin-Cu is seen to coincide with the initial rise in total 
serum enrichment. The subsequent drop in Alb-Cu %En follows an increase in total serum and Cp 
%En. This fits in with our preconceived ideas of how ingested copper is handled. The large %En 
seen on Alb reflects the relative proportion of serum copper bound to this protein. As Alb-Cu 
accounts for < 5% and Cp-Cu up to 95%, so the 65Cu dose received has a larger effect on the 
smaller amount of Alb-Cu in serum. This effect cannot be viewed in isolation as it is influenced by 
a number of other factors. The %En of Alb-Cu occurs when 65Cu absorbed by the intestinal 
mucosa enters the liver via the hepatic portal vein, is not initially stored and appears in the 
peripheral blood. In health this is influenced by the liver's capacity to store the copper or it's 
immediate requirement for it, which in turn depends upon the tissue distribution, serum Cu and 
Cp as well as bpdy weight and surface area o f the individual.
The Crohns patient with intestinal malabsorption (Graph 18, Diag.13) ^as a different pattern of 
enrichment. There is no initial rise in total serum enrichment and low Alb-Cu %En. The initial
peak at l-2hrs is usually attributed to the normal overflow of Alb-Cu from the liver. It's absence
suggests that only a small proportion o f the given dose was absorbed. This was confirmed by
measurement o f faecal copper which showed a high proportion o f 65Cu appearing immediately in
the excreta (Diag.13). There is incomplete recovery o f pellets after seven consecutive collections
which may be due to altered gut motility. The patient does not have any problem incorporating Cu
into Cp. It appears that Cp accounts for all the serum Cu in this individual as Cp %En equals total
serum %En after 72hrs. This may be due to low Alb concentrations or loss o f the Alb-Cu binding
site.
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CONCLUSIONS
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Having demonstrated the pattern of 65Cu incorporation into whole serum, it remained to be seen 
whether the technique could be refined to look at individual proteins. The investigation began 
with gel filtration chromatography. This proved to be slow and inefficient in separating the main 
copper protein fractions. Other methods were partially effective but were correspondingly flawed. 
PEG precipitation is limited to a preliminary purification step while affinity chromatography of 
albumin takes time and was often inconsistent. It was in ion exchange chromatography that a 
practical solution was found. The DEAE anion exchange gel provided the protein capacity and 
physical stability to allow the high flow rates used with FPLC. This combination was used to 
separate caeruloplasmin from serum samples taken at timed intervals post oral 65Cu dosage in four 
controls. Although there was some loss o f 65Cu enrichment during the separation procedure this 
was accounted for and an important conclusion could then be made. That is, that the secondary 
rise in total serum 65Cu enrichment closely mirrors that of chromatographically isolated 
caeruloplasmin. This procedure was subsequently used to investigate a single unaffected sibling 
from a WD kindred and three established WD heterozygotes.
A further refinement was made possible by use of 'tentacle' sepharose. Four control subjects were 
studied and ICP-MS measurements o f 65Cu on albumin confirmed that the initial rise o f total 
serum enrichments at l-2hrs was due to copper bound to this protein. The identification of two 
important copper-binding proteins of human serum resolves the components o f total serum 
enrichments and may helps formulate a model o f copper metabolism. Computer simulation o f  
copper metabolism (Blincoe 1993, Watson 1995), is greatly enhanced by such information 
allowing estimates o f whole body copper and tissue distribution. This should lead to better
79
discrimination between the numerous diseases associated with marginal copper deficiency and 
other disease (Danks 1991,Wierzbicki 1993, Logan 1994).
The applicability o f the 65Cu isotope to a wide range of research interests offers exciting 
possibilities. For cardiovascular health, copper is required as an important antioxidant (Suciu 
1992, Allen 1994). When preterm babies and infants are receiving intravenous feeding with 
potentially Cu deficient regiments, 65Cu may be used to determine the distribution and excretion of 
copper and thereby estimate true copper balance. In adults receiving intravenous feeding, or with 
severe malabsorption, the tracer may be used to determine copper status. Elderly people have 
changes in caeruloplasmin that isotope studies could clarify (Musci 1993, Semsei 1993). The 
general population might also benefit from studies on the bioavailability o f copper using 65Cu 
soiked diets (Milne 1993). The suggestion has been made that modem diets may be Cu deficient. 
The World Health Organisation (WHO) recommends 2mg/day Cu and this may not be reached for 
a number o f reasons. Traditionally, animal offal (a good source o f copper) was consumed in much 
greater amounts by the population as a whole. Copper in liver, tripe and sweetmeats is associated 
with metalloenzymes, proteins and amino acids in small stable complexes that are more readily 
absorbed than the free Cu^ ion (MAFF 1981). The modem trend is towards increased 
consumption o f highly processed foodstuffs in which the structure and composition o f ingredients 
is altered. It would be possible, by growing plants and rearing animals on 65Cu feeds to compare 
the availability o f copper from fresh and processed food.
The highly sensitive ICP-MS procedure is amenable to the study o f 65/63Cu ratios in proteins, plant 
and animal cells and tissues as well as organic material.
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METHOD 1
8 1
DESALTING AND BUFFER EXCHANGE
Since proteins differ greatly in size from salts and peptides, gel filtration is particularly efficient in 
the extraction o f sodium chloride from, and exchange or removal of solutions surrounding 
proteins. It is necessary to remove salt to prevent precipitation of proteins and to adjust the 
sample to the correct ionic conditions for ion exchange or ICP-MS work. The solution 
surrounding the proteins may require adjustment for pH, storage or replacement with pure water.
For this the low MW cut-off of the gel media Sephadex (Pharmacia) is utilised. Sephadex is a 
bead-formed gel prepared by cross-linking dextran with epichlorohydrin. In its smallest dry bead 
size (G-25 Superfine) it has a diameter o f 10-40pm supplied pre-packed (Fast Desalting Column 
HR 10/10). With a slightly larger diameter o f 50- 150pm (G-25 Medium) supplied pre-packed in 
disposable columns (PD-10). Both grades o f Sephadex have a low MW cut-off o f lkDa and any 
particles smaller than this are trapped in the gel matrix.
The sample is applied to the columns according to the following procedures to remove more than 
95% of salt originally present, elute the protein in pure water, terminate reactions or prepare it for 
subsequent chromatography.
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PD-10 Columns
Prepacked 'PD-IO* columns contain a preservative but should be checked before use for 
discoloration or drying. To achieve greater yields, samples are passed through the column twice.
INSTRUCTIONS
1. Pour off liquid on top o f column and equilibrate with 30mls of required solution.
2. Load sample in a total volume not exceeding 2.5mls. Discard eluent.
3. Elute high MW components with 3. 5mls solution - keep.
4. Re-equilibrate column with 30mls solution as before, taking the 2.5ml sample to be 
loaded from the 3.5mls already eluted.
Fast Desalting Column HR 10/10 on FPLC
1. Sample applied via Superloop in a maximum volume of 1ml.
2. Sample run at lml/min.
3. Eluted in 2-3ml volume in 1 min.
4. Re-equilibrate with 20mls required solution.
METHOD 2
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SPECTROPHOTOMETRY
Measuring the light absorbed by the column effluent at 280nm is a continuous and automatic 
method for monitoring a chromatographic separation. It depends upon chromophores in the 
protein such as the peptide bond, amino acid side chains and prosthetic groups. Before collection, 
the effluent is passed through an optical flow cell housed in the detector.
Light passing across the flow cell is registered by a photodetector and compared to a reference 
cell. The detector gives a response when an absorbing compound passes the cell. The response 
signal is plotted on a pen recorder to document retention time and resolution.
Our protein o f interest caeruloplasmin, possesses the additional quality o f being coloured. This 
allows us to measure the relative purity o f eluted fractions. Fractions as small as 1ml are measured 
in a spectrophotometer (Philips, Beckman) at 610nm against a pure water blank. By measuring 
the absorbencies at 280 and 610nm of completely pure caeruloplasmin, a corresponding ration is 
produced. This is derived from the absorbance at 610nm divided by the absorbance at 280nm. A 
90% pure caeruloplasmin preparation gives a ration o f 0.045 or better (Araauld 1988). A scan 
from 280nm to 610nm of such a preparation is presented in Diag. 14;
Diag.  14
OPTICAL SPECTRUM OF CAERULOPLASMIN
0.94530.9453
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METHOD 3
SOLVENT EXTRACTION
Samples for ICP-MS work require removal o f sodium (Na) to less than lOppm. Desalting by gel 
filtration may not always achieve this due perhaps to air bubbles or channels in the gel bed.
However, by forming a complex with a reagent and removing it into a separate solvent phase 
complete removal of sodium is ensured. The reagent used is ammonium 
pyrrolidinedithiocarbamate (APDC). It is obtained as a white crystalline substance of MW 164.3.
APDC forms complexes with more than 30 elements and most o f these complexes can be 
extracted into organic solvents. The complex with copper forms at pH 0-14 and is extracted with 
methyl isobutyl ketone (MIBK). The wide range o f metals complexed by APDC together with 
the stability o f the reagent in acid solution, make it very useful general extracting reagent for 
heavy metals. It may be used in the following ways:
(a) The concentration and/or separation o f heavy metals prior to their determination by 
atomic absorption spectrophotometry.
(b) As a qualitative reagent for the identification of metals.
(c) As a reagent for the determination of metals by spectrophotometry in the visible or 
ultra-violet regions.
(d) As a means of removing heavy metals before the EDTA titration or spectrophotometric 
determination o f elements such as magnesium, calcium, strontium, barium, aluminium or 
the lanthanons.
The protocol for ICP-MS samples is as follows:
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(1) APDC solvent extracted with MIBK three times to remove any trace metals in the APDC.
(2) Two drops Thymol Blue 2% (a pH indicator) to each sample and 7mls of deionised
water.
(3) Concentrated ammonia until greenish-yellow.
(4) Add 2mls APDC shake vigorously for 2 minutes.
(5) Add 2mls MIBK shake vigorously for 2 minutes.
(6) Remove solvent layer with pastette and heat at 150°C in an acid washed 50ml 
pyrex beaker.
(7) Cool to room temperature.
(8) Dissolve the dry extracts in 0.25ml of concentrated nitric acid followed by 0.75mls of  
deionised water.
(9) Once complete dissolution is ensured, add 8mls o f deionised water, mix by inversion 
several times and store at 4°C until analysis.
METHOD 4
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ELECTROPHORESIS
The most reliable way to determine the purity or contaminants o f a given sample is by 
electrophoresis on agarose gel. A single band is usually indicative o f 100% purity. For 
convenience, an electrophoresis kit 'Hydragel High Resolution' (Sebia) was used. The 
composition o f the gel gives better resolution than a standard agarose gel. Instead o f five or six 
fractions, this gel gives about ten or more fractions. An example is given in Diag. 15;
REAGENTS
Running Buffer: Tris 7.2 g/1
Barbital 1.8 g/1
Sodium Barbital 10.3 g/1 
Sodium Azide 0.1 g/1
Stain: 2 g/1 o f acid violet in 10% acetic acid
Fixative Solution: Ethanol 60%
Acetic acid 10%
Distilled water 30%
Destain Solution: Acetic acid 10%
PROCEDURE
(1) Dilute the serum samples 1:10 with saline. The biological fluids with low protein 
concentration must be concentrated in order to obtain about 6 g/L, o f proteins.
(2) Remove the gel from its packaging, just before sample application.
(3) Blot quickly the excess o f liquid on the gel surface, with a narrow strip o f filter paper.
(4) Place the sample template, level with the arrows. Make sure there are no air bubbles 
between the sample template and the gel.
(5) Apply 5pi o f sample on each slit. Let it diffuse for 5 minutes after last sample has been
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applied. Blot the excess sample with a template blotter.
(6) Remove the sample template.
(7) Place the gel in the tank respecting the anodic and cathodic sides.
(8) Plug the tank to the power supply and run the separation.
Running conditions are as follows:
Tank Sebia K20*
Volume of buffer per compartment 150ml
Total 300ml
Voltage (constant) 100 V
Starting current per gel 23 mA (+/-2)
Migration time 35 min
* Tank K20: the gel is positioned upside down and dips 1cm into the buffer on each side.
(9) After migration, unplug the tank and remove the gel.
(10) Rinse quickly with distilled water.
(11) Immerse the gel vertically in the fixative solution for 15 min, in the washing rack.
(12) Remove the gel from fixative and dry it with hot air at more than or equal to 60°C.
(13) Immerse the dry (and cooled) film in the staining solution for 15 min.
(14) Destain in two successive baths o f destaining solution, until the background is 
completely clear.
(15) Soak up excess liquid on the gel surface with a thin filter paper and dry the film with 
hot air approximately 60°C.
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ELECTROPHORESIS EXAMPLE
•
1 2 3 4  5 6 7  8
Key
Lane 1 : Unbound Fraction post DEAE ion exchange
Lane 2 : bound Fraction post Mono Q ion exchange
Lane 3 : bound Fraction eluted from DEAE gel
Lane 4 : bound Fraction eluted from DEAE gel
Lane 5 : bound Fraction eluted from Tentacle Sepharose
Lane 6 : bound Fraction eluted from Tentacle Sepharose
Lane 7: Single Cp band after FPLC Tentacle gel
Lane 8 : Commercial Cp ( Sigma )
METHOD 5
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COPPER BY GRAPHITE FURNACE
It was necessary, where samples contained less than 5pmol/l copper to use graphite furnace 
atomic absorption because o f it’s greater sensitivity. This method is adapted from a routine 
method for paediatric serum sar. pies and was used without any quality control (QC). Copper 
concentrations were only measured to determine the dilution required for the ICP-MS. The 
method requires a 20pl sample only. Care must be taken to avoid contamination. Acid washed 
pipette tips are used in the preparation of all reagents and standards.
PROCEDURE
Into acid-washed autoanalyser cups, pipette 200pil o f 1% Triton buffer. Add 20pl o f standard or 
sample. Mix on a vibro mixer and load cups onto graphite furnace autosampler.
INSTRUMENT CONDITIONS
For Perkin Elmer 2280 with HGA400 and AS40 autosampler:
Wavelength 325nm Injection volume 20pl
Slit width 0.7nm Chart recorder 5mV
Background correction ON Chart speed 20mm/min
Lamp current 10mA Scale Expansion X2
CALCULATION OF RESULTS
Subtract the peak height o f the O std from the peak heights o f the standards. Subtract the reagent 
blank value from the peak height for the samples. Calculated using the Trace Element Calculation 
Programme (CALGRAPH), to the nearest 0.1pmol/l.
METHOD 6
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COPPER BY FLAME AA
Samples containing copper in the range 5-30pmol/l were measured by flame atomic absorption. 
Copper concentrations were used to determine the approximate dilution required for ICP-MS 
ratio measurement. An appropriate QC was not available. This method requires a 300pl sample. 
No special precautions to avoid contamination are required, although the sample uptake tubing 
should be wiped with tissue between samples.
PROCEDURE
Samples are aspirated directly into the flame by hand and held until the read time has elapsed.
INSTRUMENT CONDITIONS 
For GBC 904AA.
Wavelength 324.7nm
Slit width 0.5nm
Background connection OFF
Lamp current 4.0mA
CALCULATION OF RESULTS
The instrument requires calibration before each run. Four standards are read and a calibration 
curve with the maximum error and R2 fit automatically produced. When the maximum error is
0.5pmol/l and the R2 fit is 0.999 or better, the samples are run without further recalibration. 
Results are automatically calculated and printed during the run.
Acetylene Flow 2 units
Air Flow 10 units
Read Time 3 s
Time Constant 0.5s
METHOD 7
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PROTEIN DETERMINATION
Caeruloplasmin concentrations were determined by single radial immunodiffusion (Behring). The 
agar plates contain monospecific antisera obtained by immunising rabbits. They are supplied in 
sealed aluminium containers containing 12 tests to be stored at 4°C.
The controls and samples are introduced undiluted into wells in the plate. The volume required 
per well is 5jff. A Hamilton1 micolitre syringe was used for this purpose.
After a diffusion period o f 2 days at 4°C the diameter of the precipitates was measured with the 
NOR-Partigen measuring template. This is accurate to the nearest 0.1mm. Having previously 
obtained false results due to outdated plates some form of quality control (QC) was required. The 
accuracy is checked by means of control plasma for NOR-Partigen. The batch dependant 
precipitate ring diameter given in the table of assigned values accompanying the pack must lie 
within the confidence range (D = +/- 0.3 mm)
The plate will measure from 70-1060mg/L caeruloplasmin.
METHOD 8
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PROTEIN CONCENTRATION
Column fractions were pooled and concentrated with a static concentrator (Nanosep). This is a 
self-standing, easy-to-use, fast and reliable system of sample enrichment prior to electrophoresis 
or further chromatography.
SPECIFICATIONS
Cut off molecular weight (Daltons) 10,000
Cells per unit 4
Cell capacity per unit 10 ml
Maximum concentration factor 200 x
Deadstop, minimum recovery 50 (j.1
S iz e (w x lx h )  37x  100 120 mm
INSTRUCTIONS FOR USE
1. Introduce the sample through the top o f each cell with a pasteur pipette or syringe.
2. If containment is required, remove backing from flap and seal the cell.
3. Concentration will proceed completely unattended. When desired concentration is 
reached, open cell and withdraw concentrate with the Intersep pipette.
4. Slow concentration in fridge at 4°C.
BENEFITS
Capable of concentrating protein solutions up to 200x.
Large capacity 10ml cells, saving time, no refilling.
Unique disposable pipette for easy withdrawal of concentrate.
Highly visible concentration levels and volume.
Non-protein binding membrane developed by Hoechst AG for Intersep allows rapid 
concentration.
Highly hydrophilic membrane surface allows complete product recovery. 
Cell can be sealed for odour containment, prevents evaporation.
50p,l dead stop avoids sample desiccation.
Desalts sample, >40% NaCl removed.
METHOD 9
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ION EXCHANGE WITH CHELEX
Chelex-100 (Bio-Rad) was used to remove loosely bound copper from caeruloplasmin after 
labelling with Cu65 (Van Berkel 1988). The chelex (0.4g) was placed into 5ml plastic tubes and 
2mls 2M nitric acid added. This was mixed on a roller mixer for 5mins to strip the resin o f any Cu 
present. The tube was then spun in a benchtop centrifuge (3,000 rpm for 5 mins), and the 
supernatant removed by pipette. The resin was converted to its ammonical form by addition of 
2mls 2M ammonia and mixing as before.
Conditioning was performed with 2mls lOOmM sodium acetate buffer pH5.5. This was done 
three times before the pH of the supernatant attained 5.5.
Incubated Cp in 2.5mls sodium acetate buffer was mixed with the prepared resin for 10 mins on 
the roller mixer. After centrifugation as described the supernatant was removed by pipette and 
prepared for ICP-MS analysis or further chromatography by FPLC.
METHOD 10
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SODIUM MEASUREMENT
Sodium concentration is measured prior to ICP-MS analysis to avoid false results caused by 
sodium-argon dimer formation. The sample must contain less than lOppm sodium to prevent 
interference.
The instrument used was the ATOMSCAN25 (Thermo Jarrell Ash), a sequential plasma emission 
spectrometer. The emission source is an inductively coupled argon plasma which provides the 
ideal excitation and is inherently stable over long time periods.
PROCEDURE
Standardisation is carried out by a two point uncalibrated method. A blank and a sodium standard 
at 11 5ppm is all that is required as the instrument has an internal standard. Samples are aspirated 
via a peristaltic pump into a nebulizer before passing into the plasma. The sample tube is 
handheld until the read time has elapsed.
INSTRUMENT CONDITIONS
Wavelength 589.592 Flush pump rate 200rpm
Radio frequency 27.12 MHz Analysis pump rate lOOrpm
Background correction YES Flush time 30s
Torch gas flow HIGH Analysis time 36s
RESULTS
Results are automatically printed during the run in ppm. These are given as the average o f two 
repeats with a percentage standard deviation. Standard deviations below 0.5% are acceptable.
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METHOD 11
COPPER ISOTOPE RATIOS BY ICP-MS
The Quadropole ICP-MS was operated under the following conditions 
Plasma:
R.f. power ........
Gas controls
Forward
Reflected
1.37 kW 
<10 W
Auxiliary 0.61 min'1
Coolant 131mm1
Nebuliser 0.71 min'1
Torch ...................................Fassel type, cooling by tangential flow
Nebuliser ..........................  Meinhart concentric type, solutions pumped at 0.7 ml min'
Spray Chamber...................  Scott-type double bypass, water cooled
Ion sampling:
Sampling cone ...................  Nickel sampler (Nicone) with 1,0-mm orifice
Skimmer cone ...................  Nickel (001 Type) with 0.75-mm orifice
Sampling distance .............  10mm from load coil
Vacuum:
Expansion stage .............  2.4 mbar
Intermediate......................... <10'4 mbar
Analyser ..............................  3-4 x 10'6 mbar
Data acquisition:
Scan mode.............................. Sweeps 1600
Dwell time 80 ps 
Channels 512
Run time 65 s
No. o f runs 5
Total time 5 mins 25 s
METHOD 12
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OXIDASE ACTIVITY OF CAERULOPLASMIN
The most common technique for the determination of the oxidase activity is based on the 
measurement o f the oxidation o f the substrate p-phenylenediamine by Cp (Sunderman 1970, 
Saenko 1990).
PRINCIPLE
Spectrophotometric measurement of the rate of formation o f the purple product following the 
oxidation o f p-phenylenediamine (PPD) by Cp.
REAGENTS
Acetate buffer, 0.1 M, pH 5.45 
Sodium azide solution 1.5 M
PPD (Sigma) solution, 27.6 mM in acetate buffer, pH 5.45.
PROCEDURE
Two millilitres of acetate buffer is mixed with 0.1 ml serum in a test tube and warmed at 37°C. 
One millilitre o f the PPD solution, also warmed at 37°C is added. The tubes are mixed, and 
incubated for exactly 30 mins at 37°C, protected from light. Fifty microlitres of sodium azide 
solution is then added, the reagents are mixed, and the sample is read in a spectrophotometer at 
530nm. The colour is stable for two hours.
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One of the sources of error when using PPD as a substrate is due to its enzymatic oxidation. To 
prevent this, a tube containing the same reagents, but to which 50jul of sodium azide (a 
irreversible inhibitor of the enzymatic oxidase activity) has been added at the beginning of the 
reaction is used as a control. The difference between this control and the reaction tube will 
determine the enzymatic oxidation of PPD. In addition, this PPD-oxidase reaction is subjected to 
a lag phase reportedly due to the oxidation by Cp o f serum ascorbic acid. Therefore, the timing 
of the reaction is deliberately delayed and the control tube receives sodium azide 5min after PPD 
is mixed with the serum sample.
CALCULATION
Cp (mg%ml) = c(Absorbance of the sample - Absorbance o f the control). Where c is a mean 
calibration factor determined by comparison with PPD-oxidase determination conducted with 
'pure' Cp preparations and calculated at 75.2. Normal values are at 31.5 (+/- 4.9 SD) mg/lOOml. 
With this method, the coefficient of variation is 1.25% and the day-to-day variability is 2.8%.
However, this procedure was not considered reproducible enough for quantification of Cp.
METHOD 13
1 0 1
CLEAN IN PLACE PROCEDURE (CIP)
Remove ionically bound proteins by washing the column with 0.5 bed volumes of a 2 M NaCl 
solution, contact time 10-15 mins, reversed flow direction.
Remove precipitated proteins, hydrophobically bound proteins and lipoproteins by washing the 
column with 1 M NaOH solution at a linear flow rate of approximately 40 cm/h, contact time 1-2 
hours, reversed flow direction.
Wash with at least 3 bed volumes o f starting buffer.
Remove strongly hydrophobically bound proteins, lipoproteins and lipids by washing the column 
with 4 bed volumes o f up to 70% ethanol or 30% isopropanol, reversed flow direction. Apply 
increasing gradients to avoid air bubble formation when using high concentrations or organic 
solvents. Trace metals are removed with one bed volume o f 200mM EDTA.
Wash with at least 3 bed volumes o f starting buffer.
METHOD 14
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METABOLIC STUDY SAMPLING PROCEDURE
1. Collect a 24 hour urine sample and a faecal sample. They do not have to be necessarily 
collected on the same day.
For urine collection - Use bottles and funnel provided. After use, rinse funnel with tap 
water and dry with paper towel.
For faeces collection - Collect urine first. Then collect stools (faeces) using the plastic 
container provided. It is important not to contaminate the faeces sample with urine.
2. Ensure diet includes plenty o f fibres. Fibres are contained in vegetables, fruits, cereals,
wholemeal bread and so on.
3. The experiment starts at 9.30 in the treatment room.
Overnight fasting is essential.
A 20 ml blood sample will be taken with a Venflon cannula, which will be left in the 
arm for the rest of the day to collect blood samples after the isotope ingestion.
The following will be given:
- two capsules of plastic pellets that will act as a faecal marker,
- 3 mg o f copper (65Cu isotope) in water.
Eating will be allowed 3 hrs after the ingestion of the isotopes.
Weight and height is recorded.
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4 BLOOD SAMPLES
Besides the first blood sample taken before the experiment, 10-20 ml blood samples will 
be collected: 0.5, 1.5, 2.0, 2.5, 3.0, 3.5, 4.5, 6.5 hrs after isotope ingestion.
A 20ml blood sample will be collected around 10.00am on Tuesday, Wednesday,
Thursday and Friday morning.
A 10ml blood sample will also be collected on three occasions a few weeks after the 
experiment.
5. URINE SAMPLES
After ingesting the isotopes, urine should be collected according to the times stated on 
the bottles. These will be, for the first day: 0-3 hr; 3-6hr; 6-12hr and 12-24 hr afto the 
experiment.
For the following 4 days (Tuesday to Friday) 24 hr urine samples will be collected 
approximately from 10.00am to 10.00am of the following day.
6 FAECAL SAMPLES
The complete faeces produced for each day from Monday to Friday, starting after the 
experiment, should be collected.
METHOD 15
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COPPER STANDARD PREPARATION
Stock Standard is BDH Copper nitrate at 15.7 mmol/L.
Working Stock (prepared fresh monthly) at 1570 pmol/1. Weigh out 18g o f water in a 25ml 
universal container (Sterilin) and add 2mls o f stock copper standard.
Preparation o f Working Standards (prepared fresh every 2 weeks)
Concentration Weigh out pis of conc. Working Stock
copper llmol/1 HjO (gins) nitric added Standard added (jJJ)
7.9 19.88 20 100
15.7 19.78 20 200
23.6 19.68 20 300
31.4 19.58 20 400
All pipette tips must be acid washed.
Standards are stored in a fridge at 4°C, and remade every four weeks.
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METHOD 16
STANDARD SERUM VALUES (Male)
Measured Values
Ref. Interval
Serum Cu 13.5 pmol/1 +/-0.3 (11.5 - 23.5)
Method
AA
Serum Cp 330 mg/1 +/-10 (200 - 500) Nephelometry
Total Protein 66g/l +/-1 (62 - 82) Olympus Analyser
Albumin 42g/l +/-1 (37 - 53) Olympus Analyser
Immunodiffusion Plate Results (average of two runs)
Ring Diameter (mm) Cp % o f Normal
Recovery from DEAE (small capacity column)
♦ Serum (2 mis) diluted 1:1 with running buffer
♦ Run at 2mls/min, collected as 3 x 2 ml fractions, measured by AAS flame:
♦ 27 pmol/Cu in original serum therefore total Cu recovery = 89%.
♦ 6mls re-concentrated to 2mls (original serum volume) and measured for;
Total Protein = 9g/l (14% of 66g/l),
Ceruloplasmin = 0.3g/l 
Albumin = 0g/l
♦ All the Albumin and 86% of total proteins removed.
1) Std Male Serum
2) Std after .45 pm filter
3) Std after DEAE
5.9
5.8
5.6
333mg/l 95
317mg/l 91
301mg/l 86
Fraction (1) 5 .9 pmol/1 or 12 pmol/Cu
(2) 9.1 pmol/1 or 18 pmol/Cu
(3) 1.9 pmol/1 or 4 pmol/Cu
total 24 pmol/Cu
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MANUFACTURERS
Amicon Ltd GBC Scientific Equipment PL Philips Analytical
Upper Mill PO Box 1226 York Street
Stonehouse Dandenong 3175 Cambridge
Gloucestershire Victoria CB1 2PX
GL10 2BJ Australia
Atlantic Antibodies- Gibco: Life Technologies Ltd Sebia: YSI Clandon Ltd
Unipath Ltd Trident House Lynchford Lane
Bedford Renfrew Road Famborough
MK41 OQG Paisley PA3 4EF Hampshire GUM 6LT
BDH: McQuilkin & Co 
21 Polmadie Avenue 
Glasgow 
G5 0BB
Becton Dickinson
Dublin
Ireland
Millipore SA 
67120 Molsheim 
France
Nanosep Filtration Systems 
Molly Millar's Lane 
Wokingham 
Berkshire RG11 2RZ
Sherwood Medical 
Crawley 
Sussex 
RH11 7YQ
Sigma Chemical Co Ltd
Fancy Road
Poole
Dorset BH17 7NH
Behring Diagnostics 
50 Salisbury Road 
Hounslow 
Middlesex 
TW4 6JH
Packard Instrument Co 
14 Station Road 
Pangboume 
Berkshire 
RG8 7DT
Sterilin Ltd 
Clockhouse Lane 
Feltham 
Middlesex 
TW14 8QS
Centrifichem 
Baker Instruments 
WhiteHall Lane 
Surrey 
TW20 9NW
Perkin Elmer 
Maxwell Road 
Beaconsfield 
Buckinghamshire 
HP9 1QA
Thermo Jarrel-Ash Corp.
8E Forge Parkway
Franklin
MA 02038
USA
Elga Ltd Pharmacia LKB VG Elemental: Fisons
Lane End 23 Grobnor Road Bishop Meadow Road
High Wycombe St Albans Loughborough
Bucks Hertfordshire Leicestershire
HP14 3JH AL1 3AW LEI 1 0RG
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